LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

8.39 0.12

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.2

Max

8.52

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Pelnas, tenkantis vienai akcijai	-0.12
Pelno marža	-13,764.773
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+59.26% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	67M 639M
Ankstesnė atidarymo kaina	8.27
Ankstesnė uždarymo kaina	8.39

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025-12-13 00:04; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025-12-14 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025-12-14 23:36; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-12-14 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025-12-14 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025-12-14 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Acquire Remaining 64% of Alta Copper

2025-12-14 17:00; UTC

Uždarbis

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025-12-14 08:30; UTC

Įsigijimai, susijungimai, perėmimai

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025-12-13 16:48; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 08:00; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 07:00; UTC

Įsigijimai, susijungimai, perėmimai

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025-12-13 00:24; UTC

Įsigijimai, susijungimai, perėmimai

Want a Piece Of SpaceX? -- Barrons.com

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

59.26% į viršų

12 mėnesių prognozė

Vidutinis 13.33 USD 59.26%

Aukščiausias 16 USD

Žemiausias 11 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.